Categories
Health

Purnell Choppin, 91, Dies; Researcher Laid Groundwork for Pandemic Struggle

In addition to his daughter, his wife Joan also survived.

After taking over the Hughes Institute, Dr. Choppin likes to tell his colleagues a story about meeting their famous reclusive benefactor. In 1938, Hughes, an accomplished aviator and industrialist, stopped at Baton Rouge to refuel, and Arthur Choppin took 9-year-old Purnell and his brother Arthur Jr. to see him. They shook hands, but his main memory was that Hughes was “very tall.”

Dr. Choppin graduated from high school at the age of 16 and went to LSU, where he also attended medical school. He received his PhD in 1953 and completed his residency at Washington University. From 1954 to 1955 he served in the Air Force in Japan.

He began as a postdoctoral fellow at Rockefeller University and was promoted to professor in 1959. He later moved into administration and was vice president and dean of studies when he was hired by the Howard Hughes Medical Institute.

Howard Hughes founded the institute in 1953 and later transferred all of his shares in the Hughes Aircraft Company to it for tax reasons.

Just a few weeks before Dr. Choppin, the institute sold the company to General Motors for $ 5.2 billion, immediately making it one of the richest philanthropists in the country.

In 1987 the president of the institute had to resign after a financial scandal and was replaced by Dr. Chopin replaced. Over the next decade, he built it into a premier source of funding for biomedical research, distributing approximately $ 4.5 billion to hundreds of scientists and elementary and high school science education.

Categories
World News

Meet the researcher attempting to get Biden to forgive pupil debt

Charlie Eaton

Courtesy: Charlie Eaton

The odds of student loan forgiveness happening have never been greater, experts say. Yet a number of large obstacles stand in the way, some practical and others ideological.

Does the president have the authority to cancel the debt? Officials at the U.S. Department of Education and the U.S. Department of Justice are currently trying to find answers to that question.

If they conclude President Joe Biden can do so, will he? And if they decide he doesn’t, will Democrats, despite their razor-thin majority, manage to pass legislation forgiving student debt?

At the center of the ideological debate, meanwhile, is the question over who would really benefit from a jubilee. A number of critics of broad student loan forgiveness say the policy would direct taxpayer dollars to people who are already relatively well-off, since college degrees lead to higher earnings.

More from Invest in You:
Almost half of Americans to take on debt as a treat post-pandemic
How to resist the urge to splurge in a post-pandemic spending spree
How to avoid overspending in this hot housing market

Biden has also questioned the fairness of canceling student debt, framing borrowers on multiple recent occasions as more privileged than others. “The idea that you go to Penn and you’re paying a total of 70,000 bucks a year and the public should pay for that? Biden said in an interview with The New York Times in May. “I don’t agree.”

And at a CNN town hall back in February, Biden said it didn’t make sense to cancel the loans “for people who have gone to Harvard and Yale and Penn.”

Now a group of scholars at the Roosevelt Institute, a progressive think tank, have published research they hope will change the minds of Biden and other critics when it comes to student loan forgiveness.

Their biggest finding is that canceling $50,000 for all student loan borrowers would wipe out more than $17,000 per person among Black households in the bottom 10% of net worth, and over $11,000 among white and Latinx households in that lowest range.

Zoom In IconArrows pointing outwards

Meanwhile, the average cancellation would be just $562 per person for those in the top 10% of net worth.

In other words: A jubilee would most benefit those who are least well-off.

CNBC spoke this week with Charlie Eaton, an economic sociologist and one of the report’s authors, about its findings and how he hopes they will impact the ongoing debate about student loan forgiveness. (The interview has been condensed and edited for clarity.)

Annie Nova: Where do you think the idea that student loan forgiveness would help those who are well-off comes from?

Charlie Eaton: Part of the myth that cancellation would help wealthy people comes from the original theory that was used to justify student loans: that individuals are better off borrowing to go to college than not going to college at all. Folks are committed to this model and justify it as something that promotes equity.

Student loan forgiveness would only be a small initial step toward redressing the economic legacy of slavery and Jim Crow. But it’s necessary.

AN: You write that race is “a glaring omission” in the arguments against student loan forgiveness. Why do you think race has been left out?

CE: A lot of the most groundbreaking work on wealth inequality has happened in the last decade. I think the newness of this knowledge is part of it. But there’s also been a willful ignorance on racial inequality by those folks who wanted to see student loans as an easy way to pay for higher education in America in place of adequate taxes and spending.

AN: You talk about student loan forgiveness as a form of racial reparations. Why?

CE: Student loan forgiveness would only be a small initial step toward redressing the economic legacy of slavery and Jim Crow. But it’s necessary to enable Black borrowers to build wealth, because Black college-goers borrow at much higher rates than white borrowers. And, as a result, it’s much harder for them to get home loans and accumulate savings.

AN: Your report expresses doubts about the effectiveness of more narrow student loan forgiveness policies, such as one that would target low-income borrowers. Why do you think a broader cancellation is the way to go?

CE: If you try to layer on these exclusions, you have greater risk of failing to undo the inequities that have been created by our student loan system. For example, if you were going to go just by income, and you said we’re not going to cancel student loans for folks who make more than $75,000 a year, you’d be excluding the disproportionate number of Black professionals who may have incomes at that level but also have much more student debt than their white counterparts.

AN: What do you see as the biggest challenge to getting student loans cancelled?

CE: Joe Biden. He seems to have accepted this myth that student debt cancellation disproportionally helps wealthier folks when the opposite is true. He has said it wouldn’t be fair to cancel debt for folks who went to Harvard or Yale or Penn. The thing is Harvard has essentially already cancelled debt for its students: Only 3% of undergraduates at Harvard have any student loan debt at all. I’m hoping our research will get through to Biden to help him understand student debt cancellation will flow to those who need it.

AN: Do you know if anyone in the Biden administration has seen your research yet?

CE: We’ve shared our work directly with White House and Department of Education staff. And we’re optimistic that the Biden administration is looking seriously at the president’s ability to cancel student debt.

The White House did not immediately respond to a request for comment.

Categories
Health

Lingering Covid signs pose ‘actually major problem,’ researcher says

A researcher studying so-called Covid long-distance drivers warned that persistent symptoms are a dire reality and can be a serious problem.

“We tracked approximately 60 different symptoms in this patient population,” said David Putrino, director of rehabilitation innovation at Mount Sinai Hospital in New York. “We really just need to focus on helping these patients and spreading awareness that this is indeed a really serious problem related to Covid.”

A new study from Northwestern University shows that 85% of long-distance drivers – Covid patients who have largely recovered from the worst illness but continue to have long-term symptoms – had four or more neurological symptoms. These symptoms include brain fog, headache, numbness or tingling, loss of taste and smell, and muscle pain.

Northwestern scientists call it the first study of its kind. It tracked 100 Covid patients, mostly women with an average age of 43 years.

Putrino told CNBC’s The News with Shepard Smith that the prevalence of long-term Covid is changing the way doctors treat patients, even with routine ailments.

“I think there were a lot of people before Covid who showed up with non-specific symptoms and they were concerned that they were being treated with formula medicine instead of being very patient-centered and symptom-centered in treatment approaches,” Putrino said. “One of the things doctors need to do now, when we see this increase in long-distance Covid activity, is listen to what patients are telling them.”

Categories
Business

A second Google A.I. researcher says the corporate fired her.

Two months after the horrific exit of a well-known artificial intelligence researcher at Google, a second AI researcher at the company said she was fired after criticizing the way employees were treated for alleviating bias and toxicity in their artificial intelligence combat systems.

Margaret Mitchell, known as Meg, one of the leaders of Google’s Ethical AI team, posted a tweet Friday afternoon saying, “I’m fired.”

Google confirmed that her employment relationship has ended. “After reviewing the conduct of this manager, we confirmed that there were several violations of our code of conduct,” the company said in a statement.

The statement went on to claim that Dr. Mitchell violated the company’s security guidelines by removing confidential documents and private employee data from the Google network. The company previously said Dr. Mitchell tried to remove such files, Axios news site reported last month.

Dr. Mitchell said Friday night that she would have public comment soon.

Dr. Mitchell’s post on Twitter comes less than two months after Timnit Gebru, the other head of the Ethical AI team at Google, said she was fired from the company after criticizing its approach to minority attitudes as well as its approach to bias AI After the departure of Dr. Gebru from the company criticized Dr. Mitchell emphatically and publicly expressed Google’s stance on the matter.

More than a month ago, Dr. Mitchell that she was banned from her work accounts. On Wednesday, she tweeted that she stayed locked out after trying to get Dr. Gebru who is black to defend.

“Exhausted from the endless deterioration to save the face of the upper crust in tech at the expense of minority minority careers,” she wrote.

Dr. Mitchell’s departure from the company was another example of the mounting tension between the top management of Google and the workforce, who are more open than those of other large companies. The news also highlighted a growing conflict in the tech industry over the bias around AI, linked to issues affecting the recruitment of employees in under-represented communities.

Today’s AI systems can bear human prejudice because they learn their skills by analyzing large amounts of digital data. Because the researchers and engineers who build these systems are often white men, many fear that researchers are not paying this topic the attention it needs.

Google announced in a blog post yesterday that a company executive, Marian Croak, who is Black, will oversee a new group within the company dedicated to responsible AI

Categories
Health

W.H.O. Researcher on His Journey to China In search of Virus Origins

What about the cases that occurred before the fish market erupted?

There were other spreads outside of the Huanan market. There are other patients unrelated to the market, some in December. There were other markets. And we know that some of the patients have had connections with other markets. We have to keep working and then our Chinese colleagues have to keep working.

When we sat down as a group, on the last full day of work, the China team and WHO team said, “Let’s go over the hypotheses.” The route that received the most enthusiastic support was this route – wildlife through a domesticated wildlife association to Wuhan .

What is the next step?

It’s straightforward for the animal chain. The suppliers are known. You know the farm name; You know the owner of the farm. You have to go to the farm and interview the farmer and family. You have to test them. You have to test the community. You need to see if there are any animals left on nearby farms, if there are any signs of infection, and if there is any cross-border movement. If the virus is in these southern border states, it is possible that there has been movement in neighboring countries like Vietnam, Laos or Myanmar. We are now finding more and more related viruses. There is one in Japan and one in Cambodia, one in Thailand.

For the human side, look for previous cases, for clusters. If possible, check the blood banks for serum. Something like this is going to be sensitive in China and it will take some persuasion, diplomacy and energy to do because, to be honest, finding the source of this virus in China is not a high priority for the Chinese government think you. Anywhere this virus appears it is a political problem. That is one of the problems and that is clear and obvious to anyone who has looked at it.

Do you have a particular animal that you currently suspect as an intermediate link stronger than others?

It’s too high in the air. We don’t know if civets were for sale. We know they get infected very easily. We don’t know what the situation is with the mink farms in China or the other fur farms like raccoon dogs, although they are usually bred in a different part of China. That too needs to be followed up.

But if you were to say which route you put the most weight on, the virus would emerge from bats in either Southeast Asia or South China and end up on a domesticated game farm. I’ve been to many of them and they often have mixed species – civets, ferret badgers, raccoon dogs. These animals could be infected by bats.

Categories
Health

David Katzenstein, AIDS Researcher With Deal with Africa, Dies at 69

This obituary is part of a series about people who died from the coronavirus pandemic. Read about others here.

Dr. David Katzenstein was perhaps a dreamer, “with sometimes brilliant and sometimes a little aloof ideas,” said a colleague recently. But from the start he was in a biosphere that spawned new undiscovered and casual killers, not an ivory tower researcher looking at the world through a microscope.

After studying medicine, he did an internship at the University of New Mexico, where his work with indigenous peoples became a permanent commitment to helping underserved populations prevent and control infectious diseases.

As a virologist and clinician, he has not only contributed to advancing the prevention, diagnosis and treatment of HIV and AIDS for 35 years. He also made these techniques available to middle- and low-income patients in sub-Saharan Africa.

Dr. Katzenstein, professor emeritus of infectious diseases and global health at Stanford Medicine, California, died on January 25 in Harare, Zimbabwe, where he had moved after retiring in 2016. He was 69 years old. The cause was Covid-19, said his stepdaughter Melissa Sanders-Self.

“Imbued with a passionate belief in social justice, David Katzenstein had an overwhelming influence on the fight against HIV in sub-Saharan Africa,” said Dr. Lloyd Minor, dean of Stanford University medical school, in a statement.

David Allenberg Katzenstein was born on January 3, 1952 in Hartford, Connecticut, to physicist Henry Katzenstein and clinical psychologist Constance (Allenberg) Katzenstein.

He graduated from the University of California at San Diego in 1973 with a bachelor’s degree in biology and received a medical degree there in 1977.

He married Sharon Mayes, who died in 2007. In addition to his stepdaughter, his sisters Ruth Souza and Amy Harrington survive him. his brother Rob Katzenstein; two bootlegs; and a step great-granddaughter.

After his stay in San Diego, Dr. Katzenstein at the University of California at Davis and the University of Minnesota until 1986.

While at the University of California, the International Antiviral Society-USA said he established a relationship with the Department of Medical Microbiology at the University of Zimbabwe Medical School and became “one of the first US-based HIV researchers to do the committed to work in this region around the world. “

From 1987 to 1989, Dr. Katzenstein as Senior Research Fellow at the Center for Biologics Evaluation and Research of the Food and Drug Administration.

In 1989, he moved to Stanford Faculty as Assistant Clinical Professor of Infectious Diseases and was appointed Assistant Medical Director of Stanford’s AIDS Clinical Trial Unit, which, among other things, conducted clinical trials of antiretroviral drugs that prolong the lives of people with HIV

He focused on the challenges posed by resistance to HIV antiviral drugs and was one of the first researchers to publicize the problem in Africa.

In Zimbabwe, he directed the Institute of Biomedical Research and Education in Harare, where he trained clinical researchers, introduced advanced diagnostic and monitoring techniques into community health programs, and continued to publish research studies until his death.

Categories
Health

Emil Freireich, Groundbreaking Most cancers Researcher, Dies at 93

Dr. Emil Freireich, a relentless cancer doctor and researcher who helped develop treatments for childhood leukemia that dramatically changed the lives of patients believed to have little hope of survival, died on February 1 at University of Texas Anderson Cancer Center at Houston. where he had worked since 1965. He was 93 years old.

His death was confirmed by his daughter Debra Ann Freireich-Bier. The hospital said it tested positive for Covid-19 but it has not yet been identified as a cause of death.

Dr. A transformative, magnetic, and occasionally aggressive personality, Freireich spent his career at the National Cancer Institute and MD Anderson researching new cancer treatments and training hundreds of doctors to follow him.

“He oversaw research in all cancers, directed and dictated the development of protocols, implemented them and published results that were adopted worldwide,” said Dr. Hagop Kantarjian, MD Anderson Leukemia Chairperson.

When Dr. Freireich (pronounced FRY-Rike) 1955 his work at the NCI in Bethesda, Md., Admission, acute childhood leukemia was viewed as a death sentence. As he walked into the ward where the children were being treated, he remembered their bleeding because their blood had practically no platelets, the disc-shaped cells that clot blood.

It was like being in a slaughterhouse, his boss, Dr. C. Gordon Zubrod.

“They bleed from their ears, from their skin,” said Dr. Freireich wrote to the author Malcolm Gladwell in “David and Goliath: Outsiders, Outsiders, and the Art of Fighting Giants” (2013). “There was blood on everything. The nurses would come to work in their white uniforms in the morning and go home covered in blood. “

Dr. Freireich, a hematologist and oncologist, tested his hypothesis that the lack of platelets was causing the bleeding by mixing some of his own blood with something from the children.

“Would it be normal?” He said in an interview for an NCI oral history project in 1997. “Sure enough.”

Further tests conducted to convince his skeptics at the Cancer Institute have proven him right.

But he had another problem: the blood the children had been given lacked the platelets necessary for blood to clot because it was at least 48 hours old. The platelets had deteriorated and were unusable.

Dr. Freireich successfully advocated the use of freshly donated blood that could be transfused as quickly as possible and that was not in the institute’s blood bank. A minister who was the father of one of the patients once brought 20 of his congregation to donate blood.

Dr. Looking for a more effective way to deliver platelets to his patients, Freireich began developing a machine to extract platelets from white and red blood cells. He soon found an unexpected ally in George Judson, an IBM engineer whose son had leukemia and who had turned up at the institute to offer his expertise.

Soon they were working on a continuous flow blood separator that was found to be far more efficient at delivering platelets than blood transfusions. (The separator, which used a high-speed centrifuge, was patented in 1966.)

Dr. However, Freireich’s most important and enduring achievement was using a combination of drugs to put leukemia into remission. He explored options in chemotherapy with several NCI colleagues, including Dr. Emil Frei III, who was known as Tom.

They aggressively attacked childhood leukemia by developing a cocktail of four drugs given at the same time – a technique similar to three-drug therapy used to treat tuberculosis – so that each one attacks a different aspect of the cancer’s physiology in cells.

“It was crazy,” said Dr. Free to Mr. Gladwell. “But smart and right. I thought about it and knew it would work. It was like the platelets. It should work! “

But not without danger and worry. Some of the children almost died from the drugs. Critics named Dr. Freireich was inhuman because he had experimented with his young patients.

“Instead, 90 percent went into remission immediately,” he told USA Today in 2015. “It was magical.” But temporarily. One round of the cocktail wasn’t enough to clear all of the cancer. Dr. Freireich and his team treated her monthly with the medication for more than a year.

When he and Dr. Frei received the renowned Albert Lasker Clinical Medical Research Award in 1972, the proportion of children who lived at least five years after being diagnosed with leukemia was 30 percent. According to the American Cancer Society, survival rates today are on regimens similar to those of Dr. Freireich and Dr. Free at 90 percent. Dr. Frei died in 2013.

Emil J Freireich was born on March 16, 1927 in Chicago. His mother Mary (Klein) Freireich worked many hours in a sweat shop after her husband David died at the age of 2. He was placed in the care of an Irish maid who became his surrogate mother. Shortly after he was nine years old, his mother remarried and quit her job. She and her new husband released the maid.

“I never forgave my mother for this,” said Dr. Free to Mr. Gladwell.

He was an excellent physicist in high school, where he won first prize in a science competition. His physics teacher encouraged him to go to college where his goal was to be a general practitioner like the one who treated his family.

“He worked for nothing and always wore a suit and tie and always looked so dignified,” said Dr. Freireich the online publication of the American Society of Clinical Oncology in 2015.

After receiving a bachelor’s degree in medicine from the University of Illinois, Chicago, in 1947, he received his medical degree from the University of Chicago’s College of Medicine, also in Chicago, in 1949.

His internship at Cook County Hospital, also in Chicago, ended after confronting a nurse for taking a patient with heart failure to what is known as the “death room” instead of keeping him on the ward where Dr. Freireich had treated him. He has been called a “troublemaker,” he said.

He then served his residency at the nearby Presbyterian Hospital (now part of Rush University Medical Center) and then moved to Boston for a fellowship at a hospital where he studied anemia. There he met a nurse, Haroldine Lee Cunningham, whom he married in 1953.

He was drafted into the Army in 1953 but was able to join the United States Public Health Service and work for the NCI, a branch of the National Institutes of Health.

When they first met, Dr. Zubrod, his boss: “Freireich, what are you doing?”

“I’m a hematologist,” recalled Dr. Freireich and watched Dr. Zubrod scratched his head and said, “Freireich, you should cure acute leukemia in children.”

And I said, “Yes sir.”

After a decade of developing therapies for childhood leukemia at the NCI, Dr. Freireich (and Dr. Frei) recruited to MD Anderson in 1965. Together, they formed the Developmental Therapeutics Division and hired scientists to develop drug combinations for different cancers, including adult leukemia, lymphoma, and Hodgkin’s disease, using the same methods used to treat childhood leukemia.

Because of his larger than life personality and his magnetism, Freireich attracted people from all over the world to study with him, ”said Dr. Kantarjian.

Dr. Freireich retired in 2015, but continued to teach and advise at MD Anderson.

In addition to his wife and wife Freireich-Bier, Dr. Freireich another daughter, Lindsay Freireich; two sons, David and Tom; six grandchildren and three great-grandchildren.

Dr. Freireich compared the early battle to cure childhood leukemia to a battle in which he and the NCI team had an alliance that was “forged under attack”.

To cure cancer, he added, “Motivate and empower people, people are naturally motivated. Nobody likes to be lazy and do nothing. Everyone wants to be important. “

Categories
Business

Oxford researcher says future strains might be protected towards

Sir John Bell, a professor at Oxford University in the UK, told CNBC on Wednesday that he was confident that Covid-19 vaccines could be upgraded to provide effective protection against future coronavirus mutations.

Bell’s comments on “Closing Bell” come as global attention is focused on a strain of the virus that is widespread in the UK and that may spread more easily than previous variants. It has since been discovered in Colorado and California.

“This is going to be a game of cat and mouse,” said Bell, who worked with AstraZeneca to oversee vaccine development at Oxford. The UK government approved emergency vaccine use on Wednesday after granting limited approval for Pfizer and BioNTech’s vaccine earlier this month.

Studies are currently underway to officially determine whether Oxford-AstraZeneca’s vaccine will protect against the new strain of the virus, Bell said. “We think they probably can, but we just want to be absolutely sure.”

“Given the level of disease in the UK with the new variant … we will have many examples of people who have had the vaccine and are exposed to the virus and we will be able to report fairly quickly on whether the vaccine actually protects against this strain,” added Bell added.

In addition to the coronavirus variant found in Great Britain, a separate strain has come into focus, which was first found in South Africa. Officials at the U.S. Centers for Disease Control and Prevention said Wednesday it may also be floating around in America.

Bell told CNBC that he believes the variant discovered in South Africa has mutations that make it “a little more worrying” than the UK’s predominant strain. Still, Bell expressed confidence in how scientists will deal with virus mutations that escape the protection of existing vaccines.

“If we need to make new vaccines, now that we’ve done the first work, we can make them. I’m sure our friends can do the same with the RNA vaccines,” said Bell. Pfizer-BioNTech and Moderna vaccines were developed using messenger RNA technology, a new approach that uses genetic material to trigger an immune response. Oxford-AstraZeneca’s viral vector vaccine uses a weakened version of a cold virus that causes infections in chimpanzees.

“We are ready if we need to make another vaccine to get closer,” added Bell. He also noted that the vaccine update development process is unlikely to require the same large-scale clinical trials conducted this year, just immunogenicity studies to ensure that an immune response is elicited.

According to Dr. It is not uncommon for viruses to mutate, Scott Gottlieb, a former Food and Drug Administration commissioner who serves on Pfizer’s Board of Directors. “Some viruses like the flu develop their surface proteins very quickly, so we need a different flu vaccine every season,” he told CNBC earlier this month.

Gottlieb said at the time that he also believed the vaccines in place will protect against the strain of virus transmitted in the UK, as the vaccines target the entire spike protein of the coronavirus.

“We are developing antibodies against many different regions of this protein. Even if part of this protein were mutated and some antibodies no longer recognized it, there would be antibodies against other parts of this protein,” he said. “That probably won’t bypass our vaccines that easily, but at some point we’ll have to update the vaccines.”

Disclosure: Scott Gottlieb is a CNBC employee and a member of the boards of directors of Pfizer, the genetic testing startup Tempus, and the biotech company Illumina. Gottlieb is also co-chair of Norwegian Cruise Line Holdings and Royal Caribbean’s Healthy Sail Panel.